CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily.
Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and …

Immune cell functions are regulated by co-inhibitory and co-stimulatory receptors. The first
two generations of cancer immunotherapy agents consist primarily of antagonist antibodies …

Immunologically-cold tumors including glioblastoma (GBM) are refractory to checkpoint
blockade therapy, largely due to extensive infiltration of immunosuppressive macrophages …

Cancer immunotherapy has revolutionized the treatment landscape in medical oncology, but
its efficacy has been variable across patients. Biomarkers to predict such differential …

Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly
in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune …

During the generation of a successful adaptive immune response, multiple molecular
signals are required. A primary signal is the binding of cognate antigen to an antigen …

Purpose: This phase I study investigated the maximum-tolerated dose (MTD), safety,
pharmacodynamics, immunologic correlatives, and antitumor activity of CP-870,893, an …

Recent success in cancer immunotherapy has reinvigorated the hypothesis that the immune
system can control many if not most cancers, in some cases producing durable responses in …

Cancer immunotherapies are more effective in tumors with robust T cell infiltrates, but
mechanisms to convert T cell-devoid tumors with active immunosuppression to those …

Background & Aims Immunotherapies that induce T-cell responses have shown efficacy
against some solid malignancies in patients and mice, but these have little effect on …